Connection

Murray Passo to Antirheumatic Agents

This is a "connection" page, showing publications Murray Passo has written about Antirheumatic Agents.
Connection Strength

1.686
  1. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Rheumatol. 2019 06; 71(6):864-877.
    View in: PubMed
    Score: 0.155
  2. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019 06; 71(6):717-734.
    View in: PubMed
    Score: 0.155
  3. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol. 2019 06; 71(6):846-863.
    View in: PubMed
    Score: 0.155
  4. Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Arthritis Rheumatol. 2019 03; 71(3):451-459.
    View in: PubMed
    Score: 0.152
  5. Use of methotrexate in children. Bull Rheum Dis. 1998 Aug; 47(5):1-5.
    View in: PubMed
    Score: 0.147
  6. Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in?Children With Polyarticular Forms of Juvenile Idiopathic?Arthritis With Clinically Inactive Disease. Arthritis Rheumatol. 2018 09; 70(9):1508-1518.
    View in: PubMed
    Score: 0.147
  7. High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy. Arthritis Rheumatol. 2018 04; 70(4):594-605.
    View in: PubMed
    Score: 0.143
  8. The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1997 Dec; 40(12):2226-34.
    View in: PubMed
    Score: 0.141
  9. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996 Nov; 129(5):630-2.
    View in: PubMed
    Score: 0.130
  10. Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol. 2008 Aug; 14(4):195-201.
    View in: PubMed
    Score: 0.074
  11. Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum. 2007 Aug 15; 57(6):1000-6.
    View in: PubMed
    Score: 0.069
  12. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006 Sep-Oct; 24(5):599-605.
    View in: PubMed
    Score: 0.064
  13. Emerging therapies in juvenile rheumatoid/idiopathic arthritis. Curr Probl Pediatr Adolesc Health Care. 2006 Mar; 36(3):97-103.
    View in: PubMed
    Score: 0.062
  14. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol. 2003 Feb; 30(2):394-400.
    View in: PubMed
    Score: 0.050
  15. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatr Rheumatol Online J. 2017 Jun 13; 15(1):50.
    View in: PubMed
    Score: 0.034
  16. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1994 Dec; 21(12):2353-8.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.